We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

65 hedge funds and large institutions have $30.9M invested in Akebia Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

475% more call options, than puts

Call options by funds: $466K | Put options by funds: $81K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

0% less capital invested

Capital invested by funds: $30.9M → $30.9M (-$36.1K)

0.2% less ownership

Funds ownership: 28.41% → 28.21% (-0.2%)

13% less funds holding

Funds holding: 75 → 65 (-10)

50% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 16

Holders
65
Holders Change
-10
Holders Change %
-13.33%
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
15
Reduced
15
Closed
16
Calls
$466K
Puts
$81K
Net Calls
+$385K
Net Calls Change
+$24K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$972K
2
AIM
Alerce Investment Management
Illinois
+$852K
3
Morgan Stanley
Morgan Stanley
New York
+$231K
4
Victory Capital Management
Victory Capital Management
Texas
+$182K
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$140K

Top Sellers

1
OCM
Ovata Capital Management
Hong Kong
-$767K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$623K
3
Renaissance Technologies
Renaissance Technologies
New York
-$418K
4
Jane Street
Jane Street
New York
-$365K
5
Millennium Management
Millennium Management
New York
-$330K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
1
Alerce Investment Management
Illinois
$9.08M +$852K +1,115,000 +7%
Vanguard Group
2
Vanguard Group
Pennsylvania
$7.01M +$972K +1,272,034 +11%
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$4.19M – – –
MFS
4
Mirabella Financial Services
United Kingdom
$1.83M +$107K +140,604 New
BlackRock
5
BlackRock
New York
$1.52M -$167K -219,022 -7%
Renaissance Technologies
6
Renaissance Technologies
New York
$1.31M -$418K -547,727 -19%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$943K – – –
Jacobs Levy Equity Management
8
Jacobs Levy Equity Management
New Jersey
$672K -$623K -816,043 -41%
Federated Hermes
9
Federated Hermes
Pennsylvania
$571K – – –
Millennium Management
10
Millennium Management
New York
$511K -$330K -431,464 -32%
State Street
11
State Street
Massachusetts
$388K +$92.4K +120,900 +21%
Morgan Stanley
12
Morgan Stanley
New York
$361K +$231K +302,988 +89%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$344K – – –
Northern Trust
14
Northern Trust
Illinois
$209K +$10.2K +13,348 +4%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$208K -$119K -155,644 -30%
Connor, Clark & Lunn Investment Management (CC&L)
16
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$170K +$140K +182,924 +152%
Group One Trading
17
Group One Trading
Illinois
$149K -$81.6K -106,771 -29%
Victory Capital Management
18
Victory Capital Management
Texas
$144K +$182K +237,922 +1,200%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$122K +$917 +1,200 +0.6%
Bank of America
20
Bank of America
North Carolina
$108K +$45.6K +59,695 +45%
Russell Investments Group
21
Russell Investments Group
United Kingdom
$106K -$2.42K -3,165 -2%
HF
22
HRT Financial
New York
$83K +$114K +148,681 New
Tudor Investment Corp
23
Tudor Investment Corp
Connecticut
$80K – – –
TSS
24
Two Sigma Securities
New York
$77.4K +$41.5K +54,269 +65%
T. Rowe Price Associates
25
T. Rowe Price Associates
Maryland
$60K -$46.9K -61,400 -37%
1
2 3 4

AKBA Hedge Fund Activity: Q1 2023 in Review

65 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2023, worth a combined $30.9M — down 0.12% from $30.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AKBA and 8 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 15 added.

The largest buyer was Vanguard Group, adding an estimated $972K. The largest seller was Ovata Capital Management, exiting entirely with an estimated $767K sold.

  • 65 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2023, down from 75 in Q4 2022.
  • Funds reported $30.9M of Akebia Therapeutics stock for Q1 2023, down 0.12% quarter-over-quarter.
  • 8 funds opened new Akebia Therapeutics positions in Q1 2023 and 16 closed out, a net change of -8 holders.
  • The largest Akebia Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $972K added.
  • The largest Akebia Therapeutics seller in Q1 2023 was Ovata Capital Management, an estimated $767K sold.

Based on aggregated 13F filings for Q1 2023.